Amphion Innovations

• 09/05/12

  Funding update

• 01/05/12

  Partner Company Update

• 28/03/12

  Partner Company Update

• 28/02/12

  Director Dealings

• 23/02/12

  Funding Update

• 

  02/02/12

  Amphion Innovations shares rise as DataTern patents are reinforced

  The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the United States Patent and Trademark Office.

• 

  15/08/11

  Amphion Innovations: on the turnaround track

  Shares in the technology commercialisation firm have recently bounced off an all-time low as it makes progress with selling software licences from its DataTern subsidiary. And it still has plenty of other irons in the fire in the shape of Partner Companies like Kromek and Motif BioSciences

• 

  02/08/11

  Amphion Innovations’ shares shoot up again after firm swings into profit

  Having already doubled its share price during the past couple of weeks, Amphion Innovations has seen a further substantial rise this morning after the firm, which commercialises university-derived intellectual property, announced a positive trading update

• 

  30/06/11

  Inherent value to be “developed and extracted” at Amphion

  Amphion Innovations is still looking to extract value from key companies in its portfolio, such as digital X-ray firm Kromek, as it publishes its results for 2010

• 

  09/09/10

  Amphion’s Unique Approach to Innovation

  Investors in Amphion should should keep an eye on further developments at Kromek. The business could be floated during Q1 2011, at which point Amphion’s 16% stake should be worth far more than the last valuation of £9m.

• 09/05/12

  Amphion Innovations gets US$500,000 loan from chairman

• 01/05/12

  Amphion Innovations’ partner Axcess reaches milestone in patent case

• 28/03/12

  Amphion Innovations partner Axcess secures up to US$10 mln credit facility

• 24/02/12

  Amphion Innovations secures additional US$500,000 loan from chairman

• 03/02/12

  Amphion Innovations secures US$500,000 loan from chairman

• 

  18/03/2010

  Amphion Innovations One2One Investor Presentation 18 March 10 (PDF)

  Amphion Innovations One2One Investor Presentation 18 March 10

The Company’s Business and Methodology

Amphion’s business is the formation, development, operation and financing of market-leading life science and technology companies in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Building upon two decades of disciplined investment and operating expertise, the building of numerous successful public and private companies, and over $20 billion in value creation, Amphion provides an opportunity to participate in both public and private early-stage investments, with a primary focus on life science and technology companies 

Amphion’s Value-Creation Process

The Directors believe that the key to Amphion’s success will be the continued pursuit of the management’s successful multi-phase process for value creation.

Through its experience in building more than 30 companies, the Management Team has developed a process which generally can be broken down into distinct phases. Set out below is a representation of Amphion’s value-creation process, showing the five key phases described in more detail.

Value-Creation Process

Phase I. Creation and sourcing of opportunities

Working with universities, corporations, governments and entrepreneurs seeking to commercialize their intellectual property, Amphion identifies potential company-building opportunities. Throughout the process, Amphion maximizes value creation by drawing upon a collaborative network of strategic partners built over 20 years. This network provides access to innovative technologies, enhances its ability to identify and address unmet market needs and solicits the guidance of industry and technical experts. While this network is a key source of opportunities, it also provides advice and counsel throughout the company-building process that may be technical, financial or business-related and ultimately helps the Partner Companies compete and grow.

Phase II. Down-selection of opportunities

Amphion devotes considerable time and resources to screening for the most attractive business models and proven technology platforms from the available opportunities. Potential opportunities must also provide a tractable corporate and ownership position to ensure that Amphion will be able to implement its company-building process.

Central to Amphion’s selection and investment strategy is rigorous risk management based on identifying companies with proven technology and a quantifiable, verifiable business opportunity. Amphion does not invest in “speculative” technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least $1 billion in size — and actively works with Partner Companies from the earliest stages to identify and defend core intellectual property (‘IP’).

For an example of our selection process, please click here

Phase III. Adaptive strategic positioning

Amphion then seeks to optimize its Partner Companies’ products and market positioning through refining or changing the emerging company’s market focus, business model, or strengthening the company management. Concurrently with this process, Amphion will undertake a review of the intellectual property, both strategic IP (i.e. what can be protected) and tactical IP (i.e. what can be protected) both to defend and expand the Partner Company’s competitive advantage and lead time over competitors.

Optimizing the business is often a “trial and error” process of rapid iteration and learning, with the objective of creating a company targeted on the greatest commercial opportunity that also provides a sustainable source of competitive advantage.

From this stage on, Amphion accelerates company development through a methodical and focused application of financial and human resources. The Management Team has traditionally adopted a hands-on approach with each new investment, seconding existing Amphion management to new Partner Companies in order to utilize Amphion’s accumulated knowledge in the company value-creation process, while gaining additional experience and insight which can be applied to subsequent investments.

Phase IV. Scaling and execution

In building its Partner Companies, Amphion typically provides a wide range of services including direct management, strategic planning, intellectual property planning and strategy, capital raising from Amphion’s network of investors, recruiting, business development, and other advisory services in areas such as marketing, administration, and capital markets. Amphion provides these services under an advisory agreement with the partner company and receives fees for doing so.

Amphion will then identify and recruit leading industry talent from its network of life science and technology partners and contacts to strengthen the management of the Partner Company, leading it to the next stage of development, generally an initial public offering or trade sale.

Phase V. Expansion and development

With an experienced industry team in place, Amphion continues to work with its companies over the long term, staying integrally involved with management, and seeking to influence and manage the boards and advisory committees to build value for both Amphion and Partner Company shareholders. To assist in this, Amphion will typically maintain a sizable ownership stake and measure of influence or control in the relevant Partner Company.

Throughout the company-building process, the Management Team strives to ensure that investor interests come before its own, and that the Company’s commitment to its Partner Companies, and investors, is a long-term one. The Company’s philosophy is to support its Partner Companies through difficult times, and provide additional management support when necessary to help them successfully weather downturns while improving their positioning for subsequent upturns.

Overview

Current Portfolio Summary (as of 26 August 2009)
Partner Companies

Company	Amphion Holding	Company Description	Valuation
	8.50%	RFID systems for a range of applications	$23 Million
	15.32%	Software platform for inter-enterprise integration	$40 Million
	19.99%	Digital x-ray systems for medical and security applications	$81 Million
	24.40%	MRI coils & tools for clinical and research use	$30 Million
	38.55%	Population genetics for pharmaceuticals and diagnostics	$33 Million
	22.14%	Molecular diagnostics for fungal diseases	$11 Million
	25.34%	Online energy trading marketplace	$17 Million
	14.56%	Nutrigenomics for health & wellness	$64 Million

Joint Ventures

Company	Amphion Holding	Company Description	Valuation
	100%	Intellectual Property Development	N/A*
	50%	Middle East Joint Venture	$6 Million

* As DataTern is 100% owned by Amphion, it is consolidated into Amphion’s financial statements.

(Updated from Amphion Innovation's website on 03 August 2011)

Robert J. Bertoldi, Executive Director

Anthony W. Henfrey, Non-executive Director

R. James Macaleer, Non-executive Chairman

Richard C. E. Morgan, Executive Director

Gerard M. Moufflet, Non-executive Director

Jerel Whittingham, Executive Director

Click here for information on Amphion's Management Team

Click here for investor information

Connect with Facebook to view or add comments for this company